Header Logo

Connection

Ian Sanne to Tuberculosis, Pulmonary

This is a "connection" page, showing publications Ian Sanne has written about Tuberculosis, Pulmonary.
Connection Strength

3,096
  1. Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
    View in: PubMed
    Score: 0,430
  2. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
    View in: PubMed
    Score: 0,333
  3. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,254
  4. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
    View in: PubMed
    Score: 0,166
  5. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
    View in: PubMed
    Score: 0,147
  6. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. BMC Pulm Med. 2019 Jan 07; 19(1):4.
    View in: PubMed
    Score: 0,125
  7. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
    View in: PubMed
    Score: 0,124
  8. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018 06 18; 67(1):34-41.
    View in: PubMed
    Score: 0,120
  9. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 01; 17(1):39-49.
    View in: PubMed
    Score: 0,107
  10. Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. Int J Tuberc Lung Dis. 2016 08; 20(8):1040-5.
    View in: PubMed
    Score: 0,106
  11. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016 May 01; 62(9):1081-8.
    View in: PubMed
    Score: 0,102
  12. The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
    View in: PubMed
    Score: 0,098
  13. High uptake of systematic HIV counseling and testing and TB symptom screening at a primary care clinic in South Africa. PLoS One. 2014; 9(9):e105428.
    View in: PubMed
    Score: 0,093
  14. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,091
  15. A home tracing program for contacts of people with tuberculosis or HIV and patients lost to care. Int J Tuberc Lung Dis. 2014 May; 18(5):534-40.
    View in: PubMed
    Score: 0,090
  16. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
    View in: PubMed
    Score: 0,089
  17. Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay. BMJ Case Rep. 2013 Aug 28; 2013.
    View in: PubMed
    Score: 0,086
  18. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,085
  19. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
    View in: PubMed
    Score: 0,083
  20. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
    View in: PubMed
    Score: 0,081
  21. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012 Sep; 17(9):1142-51.
    View in: PubMed
    Score: 0,079
  22. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7(5):e36966.
    View in: PubMed
    Score: 0,079
  23. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,075
  24. High tuberculosis and HIV coinfection rate, Johannesburg. Emerg Infect Dis. 2007 May; 13(5):795-6.
    View in: PubMed
    Score: 0,056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.